UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.461

Sortiert nach

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

Annals of oncology, 2011-02, Vol.22 (2), p.335-340

2011

Volltextzugriff (PDF)

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

British journal of cancer, 2013-08, Vol.109 (4), p.943-949

2013

Volltextzugriff (PDF)

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

European journal of cancer (1990), 2006-08, Vol.42 (12), p.1875-1880

2006

Volltextzugriff (PDF)

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

British journal of cancer, 2006-04, Vol.94 (8), p.1136-1143

2006

Volltextzugriff (PDF)

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Annals of oncology, 2021-06, Vol.32 (6), p.757-765

2021

Volltextzugriff (PDF)

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Annals of oncology, 2012-01, Vol.23 (1), p.238-244

2012

Volltextzugriff (PDF)

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

Annals of oncology, 2017-04, Vol.28 (4), p.727-732

2017

Volltextzugriff (PDF)

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Gynecologic oncology, 2012-04, Vol.125 (1), p.136-140

2012

Volltextzugriff (PDF)

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Annals of oncology, 2022-10, Vol.33 (10), p.1021-1028

2022

Volltextzugriff (PDF)

How to assess the potential interest of aspirin in ovarian cancer?

Cancer epidemiology, 2015-10, Vol.39 (5), p.790-791

2015

Volltextzugriff (PDF)

Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian Cancer

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1266-1274

2001

Volltextzugriff (PDF)

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Annals of oncology, 2018-04, Vol.29 (4), p.917-923

2018

Volltextzugriff (PDF)

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

Gynecologic oncology, 2015-07, Vol.138 (1), p.55-61

2015

Volltextzugriff (PDF)

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)

Gynecologic oncology, 2003-04, Vol.89 (1), p.129-133

2003

Volltextzugriff (PDF)

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Gynecologic oncology, 2017-02, Vol.144 (2), p.250-255

2017

Volltextzugriff (PDF)

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients

Gynecologic oncology, 2019-05, Vol.153 (2), p.304-311

2019

Volltextzugriff (PDF)

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-10, Vol.390 (10106), p.1949-1961

2017

Volltextzugriff (PDF)

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review

International journal of gynecological cancer, 2007-11, Vol.17 (6), p.1194-1204

2007

Volltextzugriff (PDF)

Germline BRCA1 / 2 testing practices in ovarian cancer: Current state and opportunities for new directions

Gynecologic oncology, 2016-01, Vol.140 (1), p.90-94

2016

Volltextzugriff (PDF)

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial

Annals of oncology, 2018-10, Vol.29, p.viii727-viii727

2018

Volltextzugriff (PDF)

Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast Cancer

Journal of clinical oncology, 1999-10, Vol.17 (10), p.3082-3090

1999

Volltextzugriff (PDF)

Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

Annals of oncology, 2018-10, Vol.29, p.viii340-viii341

2018

Volltextzugriff (PDF)

Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Annals of oncology, 2018-10, Vol.29, p.viii340-viii340

2018

Volltextzugriff (PDF)

Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3

Annals of oncology, 2018-10, Vol.29, p.viii338-viii339

2018

Volltextzugriff (PDF)

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial

Annals of oncology, 2018-11, Vol.29, p.ix174-ix175

2018

Volltextzugriff (PDF)

1 – 25 von 1.461

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.315)
Mit Volltextzugriff
(1.293)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.456)
Japanisch
(102)
Französisch
(4)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(243)
Annals Of Oncology
(73)
International Journal Of Gynecological Cancer
(66)
Gynecologic Oncology
(48)
Clinical Cancer Research
(43)
The Lancet Oncology
(23)
European Journal Of Cancer
(18)
The Lancet
(18)
Cancer
(14)
Current Science
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

How to assess the potential interest of aspirin in ovarian cancer?

Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian Cancer

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review

Germline BRCA1 / 2 testing practices in ovarian cancer: Current state and opportunities for new directions

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial

Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast Cancer

Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial

Suchergebnisse filtern